Kamada (KMDA) Current Deferred Revenue (2012 - 2026)
Kamada (KMDA) posted quarterly Current Deferred Revenue of $67000.0 for Q1 2026, down 67.32% year-on-year from $205000.0 in Q1 2025, and down 93.44% on a QoQ basis from $1.0 million in Q3 2025.
Kamada (KMDA) Current Deferred Revenue (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Current Deferred Revenue for 15 consecutive years, with $67000.0 the latest figure, recorded in Q1 2026.
- Quarterly Current Deferred Revenue fell 67.32% year-over-year to $67000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67000.0 (down 67.32% YoY) and the FY2024 annual result came in at $171000.0, up 15.54% from the prior year.
- Current Deferred Revenue slipped to $67000.0 in Q1 2026 per KMDA's latest filing, from $1.0 million in the prior quarter.
- Over the last five years, Current Deferred Revenue for KMDA reached as high as $1.0 million in Q3 2025 and fell as low as $40.0 in Q3 2022.
- A 5-year average of $128278.7 and a median of $40000.0 in 2022 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue tumbled 100.0% — and 2023, when it jumped 37400.0%.
- Year by year, Current Deferred Revenue stood at $35000.0 in 2022, then jumped by 322.86% to $148000.0 in 2023, then rose by 15.54% to $171000.0 in 2024, then surged by 497.66% to $1.0 million in 2025, then sank by 93.44% to $67000.0 in 2026.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $67000.0, $1.0 million, and $177000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67,000.00 |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 177,000.00 |
| Mar 31, 2025 | 205,000.00 |
| Dec 31, 2024 | 171,000.00 |
| Sep 30, 2024 | 41,000.00 |
| Jun 30, 2024 | 27,000.00 |
| Mar 31, 2024 | 26,000.00 |
| Dec 31, 2023 | 148,000.00 |
| Sep 30, 2023 | 15,000.00 |
| Jun 30, 2023 | 38,000.00 |
| Mar 31, 2023 | 419.00 |
| Dec 31, 2022 | 35,000.00 |
| Sep 30, 2022 | 40.00 |
| Jun 30, 2022 | 40,000.00 |
| Mar 31, 2022 | 40,000.00 |
| Dec 31, 2021 | 40,000.00 |
| Sep 30, 2021 | 3.58 Mn |
| Jun 30, 2021 | 3.03 Mn |
| Mar 31, 2021 | 2.53 Mn |